Michael Townsend
About Michael Townsend
Michael Townsend's Role as Head of Translational Biology
Michael Townsend holds the position of Head of Translational Biology. In this role, he leads efforts to understand disease mechanisms, discover biomarkers, and implement reverse translation. His work supports biomarker discovery, strategy development, and clinical implementation through all drug development phases. Townsend has shown commitment and expertise in directing a translational research department to advance therapeutic insights.
Michael Townsend's Career at Genentech
Michael Townsend has accumulated 18 years of experience at Genentech, where he has held positions of increasing responsibility. His work spans a broad range of therapeutic areas and indications. During his tenure, Townsend has significantly contributed to the company's growth in translational biology and biomarker research, in turn, aiding in the advancement of many drug development projects.
Michael Townsend's Academic Background
Michael Townsend earned a B.Sc. in Biochemistry from Imperial College London, followed by a Ph.D. in Immunology and Molecular Biology from the University of Cambridge. After his doctorate, Townsend completed postdoctoral research in the laboratory of Laurie Glimcher, M.D., at the Harvard School of Public Health. These academic experiences have provided him with a strong foundation in biological sciences and immunology, propelling his career in translational research.
Michael Townsend's Research Contributions
Michael Townsend is a prolific contributor to scientific research, co-authoring over 50 primary research papers and review articles throughout his career. His work has been influential in the fields of biomarker discovery and drug development. Additionally, Townsend is an inventor on five patents, demonstrating his role in innovative research and development within the biopharmaceutical industry.
Michael Townsend's Contributions to Drug Development
Michael Townsend has played a vital role in supporting the drug development process. His contributions to multiple Investigational New Drug (IND) filings underscore his commitment to translational research. Townsend's expertise in biomarker strategy development and implementation is integral to advancing drugs from the research phase into clinical trials, thereby supporting the creation of new therapeutic options.